Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
AJ Weickhardt, DS Williams, CK Lee, F Chionh, J Simes, C Murone, K Wilson, MM Parry, K Asadi, AM Scott, CJA Punt, ID Nagtegaal, TJ Price, JM Mariadason, NC Tebbutt
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2015
Awarded by NHMRC
The MAX study was supported by an unrestricted educational grant from Roche Products Pty Limited (Australia) and an additional untied educational grant from Roche Products Ltd (United Kingdom). The study was also supported by grants for infrastructure to the National Health and Medical Research Council (NHMRC) Clinical Trials Centre from Cancer Australia, the Cancer Institute New South Wales, and the NHMRC (1037786).